RegeneRx Biopharmaceuticals Inc. (OTC:RGRX) had its target price reduced by HC Wainwright from $2.00 to $1.50 in a research report released on Wednesday morning, StockTargetPrices.com reports. HC Wainwright currently has a buy rating on the stock.

Separately, ValuEngine cut shares of RegeneRx Biopharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 1st.

Shares of RegeneRx Biopharmaceuticals (OTC:RGRX) opened at $0.29 on Wednesday. The stock has a market cap of $31.00, a P/E ratio of 29.00 and a beta of -2.70. The company has a current ratio of 0.39, a quick ratio of 0.39 and a debt-to-equity ratio of -0.10. RegeneRx Biopharmaceuticals has a 1 year low of $0.22 and a 1 year high of $0.40.

WARNING: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-trims-regenerx-biopharmaceuticals-inc-rgrx-target-price-to-1-50/1680076.html.

RegeneRx Biopharmaceuticals Company Profile

RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.

Stock Target Prices

Receive News & Ratings for RegeneRx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.